Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: pharmaceutical-industry-labor-management-association.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
20 filings
$403K on those filings
Medicare/Medicaid
MMM
11 filings
$410K on those filings
Labor Issues/Antitrust/Workplace
LBR
2 filings
$60K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
118th Congress
DRUG Act
11 filingsthrough 2024
S. 113118th CongressPrescription Pricing for the People Act of 202310 filingsthrough 2024
S. 127118th CongressPharmacy Benefit Manager Transparency Act of 202310 filingsthrough 2024
S. 1542118th CongressDRUG Act8 filingsthrough 2024
H.R. 1492119th CongressTo amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.7 filingsthrough 2026
H.R. 4895118th CongressLowering Drug Costs for American Families Act7 filingsthrough 2024
H.R. 3117th CongressElijah E. Cummings Lower Drug Costs Now Act7 filingsthrough 2021
S. 1040119th CongressDrug Competition Enhancement Act6 filingsthrough 2026
H.R. 4317119th CongressPBM Reform Act of 20255 filingsthrough 2026
H.R. 5378118th CongressLower Costs, More Transparency Act5 filingsthrough 2024
S. 1339118th CongressPharmacy Benefit Manager Reform Act5 filingsthrough 2024
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
Covered position:
18 filingsthrough 2015
Corey MalmgrenTiber Creek GroupCovered position: Sen. Bill Nelson, Deputy Legislative Director & Health Counsel (2015-2018); Rep. Sandy Levin, Legislative Counsel (2013-2015), Legislative Correspondent, Staff Assistant (2008-2009); House Committee on Ways and Means, Legal Clerk/Intern (2010)11 filingsthrough 2026
Michael MaitlandMccarter & English, LLPCovered position: Lobbyist9 filingsthrough 2026
Gerald BakerGerald Baker8 filingsthrough 2010
Christopher HeinzGrossmanheinz4 filingsthrough 2019
Covered positions · 4 of 9 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
